Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Tumor Biology

Abstract #153: Cox-2 inhibition delays resistance to sunitinib in RCC xenograft models

Rupal Bhatt, Xiaoen Wang, Liang Zhang, Andrea Bullock, Manoj Bhasin, Towia Libermann, Sabina Signoretti, Anne O'Neill, Michael Atkins, James Mier and S. Goldberg
Rupal Bhatt
Beth Israel Deaconess Medical Ctr., Boston, MA; Brigham and Women's Hospital, Boston, MA; Dana/Farber Harvard Cancer Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoen Wang
Beth Israel Deaconess Medical Ctr., Boston, MA; Brigham and Women's Hospital, Boston, MA; Dana/Farber Harvard Cancer Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liang Zhang
Beth Israel Deaconess Medical Ctr., Boston, MA; Brigham and Women's Hospital, Boston, MA; Dana/Farber Harvard Cancer Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Bullock
Beth Israel Deaconess Medical Ctr., Boston, MA; Brigham and Women's Hospital, Boston, MA; Dana/Farber Harvard Cancer Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manoj Bhasin
Beth Israel Deaconess Medical Ctr., Boston, MA; Brigham and Women's Hospital, Boston, MA; Dana/Farber Harvard Cancer Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Towia Libermann
Beth Israel Deaconess Medical Ctr., Boston, MA; Brigham and Women's Hospital, Boston, MA; Dana/Farber Harvard Cancer Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabina Signoretti
Beth Israel Deaconess Medical Ctr., Boston, MA; Brigham and Women's Hospital, Boston, MA; Dana/Farber Harvard Cancer Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne O'Neill
Beth Israel Deaconess Medical Ctr., Boston, MA; Brigham and Women's Hospital, Boston, MA; Dana/Farber Harvard Cancer Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Atkins
Beth Israel Deaconess Medical Ctr., Boston, MA; Brigham and Women's Hospital, Boston, MA; Dana/Farber Harvard Cancer Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Mier
Beth Israel Deaconess Medical Ctr., Boston, MA; Brigham and Women's Hospital, Boston, MA; Dana/Farber Harvard Cancer Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Goldberg
Beth Israel Deaconess Medical Ctr., Boston, MA; Brigham and Women's Hospital, Boston, MA; Dana/Farber Harvard Cancer Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

Cox-2 inhibition delays resistance to sunitinib in RCC xenograft models Background: Renal cell carcinoma (RCC) has been found to be responsive to agents that inhibit the vascular endothelial growth factor receptor (VEGFR). Sunitinib, a tyrosine kinase inhibitor of VEGFR, is effective at producing tumor responses; however, resistance to therapy develops at a median of 11 months. Murine xenograft models of acquired sunitinib resistance were generated and transcriptional analyses of resistant tumors showed arginase, a known cox-2-induced protein, to be increased at the time of resistance. Thus, we assessed the effect of the cox-2 inhibitor celecoxib on acquired resistance to sunitinib in these models. Methods: Mice bearing xenografts derived from two RCC cell lines that showed resistance after stabilization on sunitinib, 786-O and A498, were treated when tumors reached 12mm with celecoxib, sunitinib (25mg/kg and 53.6 mg/kg, respectively daily by gavage), the combination or PBS control and growth curves were generated. Tumors were also followed by arterial spin labeled (ASL) MRI to measure changes in tumor perfusion. Results: Mice treated with the combination of sunitinib and celecoxib had significantly longer periods of tumor stabilization compared to those treated with either agent alone or PBS controls (Table). There was a 38% and 50% increase in the time of tumor stabilization with the addition of celecoxib to sunitinib in 786-O and A498 cells, respectively. Additionally, perfusion imaging showed that the combination of sunitinib and celecoxib suppressed tumor perfusion longer than either agent alone or PBS controls. Conclusions: Cox-2 inhibition is a potential means to delay resistance to VEGFR inhibition in RCC. Further exploration, including potential clinical studies of this combination in patients with metastatic RCC is warranted.$$table_{A96D4818-3AE1-4105-8B0C-8E296506CFC6}$$ Table: Length of tumor stabilization with therapy as defined as days for the tumor to grow by 2mm from pretreatment size. *=p<0.01

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 153.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #153: Cox-2 inhibition delays resistance to sunitinib in RCC xenograft models
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #153: Cox-2 inhibition delays resistance to sunitinib in RCC xenograft models
Rupal Bhatt, Xiaoen Wang, Liang Zhang, Andrea Bullock, Manoj Bhasin, Towia Libermann, Sabina Signoretti, Anne O'Neill, Michael Atkins, James Mier and S. Goldberg
Cancer Res May 1 2009 (69) (9 Supplement) 153;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #153: Cox-2 inhibition delays resistance to sunitinib in RCC xenograft models
Rupal Bhatt, Xiaoen Wang, Liang Zhang, Andrea Bullock, Manoj Bhasin, Towia Libermann, Sabina Signoretti, Anne O'Neill, Michael Atkins, James Mier and S. Goldberg
Cancer Res May 1 2009 (69) (9 Supplement) 153;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Tumor Biology

  • Abstract SY34-04: Do we need to know what pO2 hypoxia is
  • Abstract SY28-04: Rational incorporation of novel agents into multimodality treatment of glioma and neuroblastoma
  • Abstract SY28-02: Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment
Show more 3

Angiogenesis Inhibitors 2 -- Poster Presentations - Proffered Abstracts

  • Abstract #159: Suppression of heat shock Protein 27 induces long-term dormancy in human breast cancer
  • Abstract #162: Identification of domains of human endothelial nitric oxide synthase protein that strongly suppress tumor growth in vivo
  • Abstract #152: Celecoxib resistance in the Min/+ mouse intestine is associated with angiogenesis via NF-\#954;B-mediated adaptation of myofibroblasts
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement